07.09.26 -- Why Contamination Control By Design Still Falls Short In CDMOs

Watch as our CGT experts explore the evolving landscape of viral vector manufacturing, overcoming production bottlenecks, and the strategies necessary to bring life-changing therapies to more patients.

Manufacturing and quality gaps drive most FDA Complete Response Letters in cell therapy, often stemming from early‑stage decisions and unresolved CMC issues that become major approval risks.

Supply chain visibility and proactive risk strategies are vital to navigate new federal biotech restrictions and protect drug development pipelines.

A technical overview of minimizing product loss in aseptic fill‑finish processes, highlighting key loss points and practical strategies to improve yield, efficiency, and manufacturing consistency.

Scale-out manufacturing speeds commercial launch by using modular single-use systems that preserve process consistency, reduce comparability risk, and align capacity with demand.

Early risk identification is critical to predictable technology transfer. Learn how data-driven modeling, multivariate analysis, and proactive collaboration help keep manufacturing timelines on track.

Predictive in silico modeling accelerates biologics development by identifying stability and formulation risks early, enabling smarter candidate selection, reduced costs, and improved success rates.

Adding 0.2% soy peptone to chemically defined media increases CHO IgG production by 30–60%. This animal-free supplementation enhances titers while maintaining high process control.

Pharma and biotech developers rely on adaptable fill‑finish capacity to meet evolving market demands, scale products from clinical to commercial, and respond rapidly to public‑health emergencies.

Technology can transform the entire biopharma production process chain. Using integrated process models, machine learning, and genetic algorithms has made production faster and more efficient.

As demand forecasts evolve, opt to work with a CDMO that can pivot manufacturing strategies seamlessly while accommodating your end-to-end needs, from drug substance to finished goods.

Uncover current and emerging technologies to optimize mRNA manufacturing, especially when considering commercial production and the validation of processes in a cGMP environment.